Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Eligibility Criteria

• * Patients that are seen at MD Anderson Cancer Center
• * Patients with pancreatic ductal adenocarcinoma (PDAC) diagnosis who are expected to have surgery (Whipple)
• * Adequate hematological function, defined by white blood cell (WBC) count ≥ 3,000/microL, platelet count ≥75,000/microL, and Hgb ≥ 8 g/dL
• * Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN), an AST, level ≤ 2.5 × ULN, and an ALT level ≤ 2.5 × ULN
• * Adequate renal function defined by an estimated creatinine clearance \>30 mL/min according to the Cockcroft-Gault formula or by a creatinine clearance measurement from a 24-hour urine collection
• * Age 18 years and above
• * Male or female
• * Willingness and ability to sign an informed consent
• * Consent and ability to give blood and stool samples
• * Consent to undergo a baseline core biopsy and colonoscopy for FMT delivery
• * An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• * Age younger than 18 years
• * Positive GI infection
• * Patients with pancreatic cancer Stage T1N0
• * Individuals at higher risk of colonization with MDROs
• * Patient received antibiotics in the last 48 hours. Patients will be eligible to enroll if antibiotic therapy is discontinued for at minimum 48 hours prior to start of study
• * Patients with active viral, bacterial or fungal infection
• * History of inflammatory bowel disease, and/or radiation enteritis or colitis
• * Pregnant and breastfeeding women
• * Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test
• * Has a diagnosis of immunodeficiency
• * Peripheral WBC \>12 x 10\^9/L and/or temperature \>38 degrees Celsius
• * Subjects with neutropenia (ANC \<1500)
• * Swallowing dysfunction or known chronic aspiration
• * Delayed gastric emptying
• * History of intestinal obstruction
• * Acute exacerbation of underlying comorbid condition
• * Severely immunocompromised patients
• * Allergies to drugs included as part of trial (antibiotics, loperamide or laxatives)